Released May 10, 2017, after the close
10-Q filed May 10, 2017, 40 days after period end · 0001390478-17-000036
Q1 2017 · 10-Q
Revenue—
Net Income-$4.60M-$4.60M N/M vs Q1 2016N/M vs Q4 2016
EPS Diluted-$3.63-$3.63 no prior Q1 2016 on fileno prior Q4 2016 on file
Operating Income-$5,088,000N/M
Operating Cash Flow-$3,803,000N/M
What the release said
The release
Same quarter
| Metric | Q1 2017 | Q1 2016 | Q1 2015 | Q1 2014 |
|---|---|---|---|---|
| Revenue | — | — | $2.75M | $2.17M |
| Net Income | -$4.60M | -$16.49M | -$10.54M | -$2.54M |
| EPS Diluted | -$3.63 | — | -$0.08 | -$0.02 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR